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Recurrent somatic mutations 
and low germline predisposition 
mutations in Korean ALL patients
Sang‑Yong Shin1, Hyeonah Lee2, Seung‑Tae Lee3*, Jong Rak Choi3, Chul Won Jung4, 
Hong Hoe Koo5 & Sun‑Hee Kim6*
In addition to somatic mutations, germline genetic predisposition to hematologic malignancies is 
currently emerging as an area attracting high research interest. In this study, we investigated genetic 
alterations in Korean acute lymphoblastic leukemia/lymphoma (ALL) patients using targeted gene 
panel sequencing. To this end, a gene panel consisting of 81 genes that are known to be associated 
with 23 predisposition syndromes was investigated. In addition to sequence variants, gene‑level copy 
number variations (CNVs) were investigated as well. We identified 197 somatic sequence variants and 
223 somatic CNVs. The IKZF1 alteration was found to have an adverse effect on overall survival (OS) 
and relapse‑free survival (RFS) in childhood ALL. We found recurrent somatic alterations in Korean ALL 
patients similar to previous studies on both prevalence and prognostic impact. Six patients were found 
to be carriers of variants in six genes associated with primary immunodeficiency disorder (PID). Of 
the 81 genes associated with 23 predisposition syndromes, this study found only one predisposition 
germline mutation (TP53) (1.1%). Altogether, our study demonstrated a low probability of germline 
mutation predisposition to ALL in Korean ALL patients.
B-cell precursor and T-cell precursor acute lymphoblastic leukemia/lymphoma (B-ALL, T-ALL) are two of the 
most common malignancies in children. ALL can be classified by genetic alterations, which are highly various 
and heterogeneous. Chromosome aneuploidy, structural alterations and rearrangements, copy number varia-
tions (CNVs), and sequence mutations all contribute to leukemogenesis. In 2016, the fourth edition of the World 
Health Organization (WHO) classification of lymphoid and myeloid neoplasms and acute leukemia included 
new provision entities of ALL: BCR-ABL1-like (or Ph-like) ALL, iAMP21 (intrachromosomal amplification of 
chromosome 21), and early T-cell precursor ALL (ETP-ALL)1.
BCR-ABL1-like ALL is a high-risk form of ALL with its peak incidence in young adults. IKZF1 deletions, 
mutations of JAK-STAT and RAS signaling genes (NRAS, KRAS, PTPN11, NF1, etc.), and structural rearrange-
ments (CRLF2, ABL-class tyrosine kinase genes, JAK2, EPOR, etc.) have been identified in this  group2. iAMP21 
accounts for about 2% of ALL in older children, and it is associated with a number of adverse  outcomes3. In 
iAMP21, three or more additional copies of RUNX1 (AML1) are observed on chromosome 21 in metaphase 
fluorescence in situ hybridization (FISH). ETP-ALL is defined as  CD1a−,  CD8−,  CD5− (dim), and positive for one 
or more stem-cell or myeloid antigens. Genetic alterations in ETP are somewhat different than those in non-ETP, 
and FLT3, DNMT3A, and WT1 mutations are more often found in ETP than in non-ETP4, 5.
In addition to somatic mutations, germline genetic predisposition to hematologic malignancies has emerged 
as an area of research interest. Genes found to be associated with predisposition to myeloid malignancy have been 
included in the WHO classification, “Myeloid neoplasms with germ line predisposition”1; this category includes 
CEBPA, DDX41, RUNX1, ANKRD26, ETV6, GATA2, and others. A number of syndromes, such as bone marrow 
failure syndrome and telomere biology disorders, are also included in that category. One early study estimated 
that childhood leukemia with hereditary genetic causes accounted for 2.6% of all  cancers6. Down syndrome 
(DS) is the most common underlying genetic predisposition for  ALL6, 7. There are a number of other syndromes 
that also increase susceptibility to ALL, such as Li Fraumeni (TP53), Bloom syndrome (BLM), Wiskott Aldrich 
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syndrome (WAS), ataxia telangiectasia (ATM), and Nijmegen breakage syndrome (NBN)8. A germline mutation 
of PAX5 is highly susceptible to the development of B-ALL9.
Some genes associated with ALL are found to have both germline and somatic mutations. For example, PAX5, 
ETV6, TP53, and IKZF1 are known to have important somatic alterations, and germline mutations of those 
genes also cause susceptibility to ALL. Further, somatic and germline mutations of those genes can be found at 
the same time in leukemic  samples9, 10. Therefore, upon initial ALL diagnosis, discrimination between somatic 
and germline mutations is a crucial aspect of accurately classifying ALL patient genetic subtypes/risk groups 
and detecting predisposition genes.
In this study, we used extensive gene panel sequencing to investigate genetic alterations (both somatic and 
germline) in Korean ALL patients; we also evaluated the clinical significance of recurrent somatic mutations and 
germline predisposition mutations in Korean ALL patients.
Results
Patients. Table 1 summarizes the characteristics of all 93 enrolled Korean ALL patients that are examined 
in this study. We enrolled 65 pediatric (< 20 years old) ALL patients and 28 adult ALL patients; this population 
included 12 T-ALL patients (seven children, five adults). 
B-ALL with BCR-ABL1 was the most common form of adult B-ALL (11/23). B-ALL, hyperdiploidy and 
B-ALL, and NOS were the most common forms of childhood B-ALL (41/58). B-ALL with t(12;21)(p13.2;q22.1); 
ETV6-RUNX1 and B-ALL with t(v;11q23.3); KMT2A rearrangement respectively occurred in nine patients and 
four patients. The immunophenotyping results indicate that two adults with T-ALL were diagnosed with early 
T-cell precursor acute leukemia.
B-ALL was divided into three risk groups based on the classifications presented in a previous  study11: (1) 
Good risk; ETV6-RUNX1 and high hyperdiploidy (51–65 chromosomes); (2) Intermediate risk; TCF3-PBX1, 
IGH translocations and B-other (none of these established abnormalities); and (3) High risk; BCR-ABL1, KMT2A 
translocations, near haploidy (30–39 chromosomes), low hypodiploidy (less than 30 chromosomes), iAMP21, 
and TCF3-HLF.
Germline sequence variants among 23 syndrome‑associated genes. Pathogenic or likely patho-
genic variants. Only one TP53 variant was identified (Table 2). The TP53 NM_000546.5: c.733G > A variant 
was identified in a B-ALL, NOS patient. The TP53 NM_000546.5: c.733G > A variant has previously been report-
ed in Li-Fraumeni syndrome patients (multiple cancers, including breast cancer, liver cancer, and lung cancer)12.
Germline copy number variants. Only one patient (male, 18 years old, B-ALL-NOS) had a known CNV, CASP10 
(deletion of exon 6-exon 9 which contained the CASc domain, as shown in Supplemental Fig.  S1, Table 2). 
This same CNV was previously found in a patient with systemic juvenile idiopathic arthritis with incomplete 
 penetrance13. CASP10 is a causative gene for autoimmune lymphoproliferative syndrome (ALPS) type IIa, and 
its mutation hot spot is the protease domain (CASc) with missense mutation. However, our patient with the 
CASP10 CNV has no clinical symptoms consistent with ALPS.
Table 1.  Clinical characteristics of 93 ALL patients. (1) good risk—ETV6-RUNX1 and high hyperdiploidy 
(51–65 chromosomes); (2) intermediate risk—TCF3-PBX1, IGH translocations, B-other (none of these 
established abnormalities); (3) high risk—BCR-ABL1, KMT2A translocations, near haploidy (30–39 






B-ALL, NOS 25 8
B-ALL with t(9;22)(q34.1;q11.2); BCR-ABL1 2 11
B-ALL with t(v;11q23.3); KMT2A rearranged 4 1
B-ALL with t(12;21)(p13.2;q22.1); ETV6-RUNX1 9
B-ALL with hyperdiploidy 16 1
B-ALL with t(1;19)(q23;p13.3); TCF3-PBX1 2 2
T-ALL 5 5
Early T-cell precursor acute leukemia 2
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PID-associated germline sequence variants. Five PID-associated gene variants were identified in five patients 
(Supplement Table S1). All these variants were heterozygous autosomal recessive (AR) PID associated variants. 
Three variants (IL12RB1, CTC1, and LPIN2) have yet to be published, while the other variants (TYK2 and LIG4) 
were known variants.
Overall somatic alteration of B-ALL and T-ALL. The most common genetic alterations are shown in Fig.  1 
(T-ALL) and Fig. 2 (B-ALL). The most common genetic alterations of T-ALL were NOTCH1 (50%), CDKN2A/B 
(50%), IL7R (25%), FBXW7 (25%), GATA3 (25%), and NRAS (25%). The most common genetic lesions in T-ALL 
were NOTCH (58%), Chromatin structure modifiers and epigenetic regulators (58%), and the cell cycle/p53 
signaling pathway (58%) (Supplement Fig. S2).
The most common (> 10%) genetic alterations of B-ALL were CDKN2A/B (31%), NRAS (17%), IKZF1 (17%), 
PAX5 (16%), ETV6 (15%), FLT3 (14%), ERG (12%), and RB1 (11%). The most common genetic lesions in B-ALL 
were symphoid development and differentiation (49%), the cell cycle/p53 signaling pathway (42%), and the RAS 
pathway (36%) (Supplement Fig. S3).
Somatic sequence variants. We identified 197 variants after excluding synonymous variants (Supple-
ment Table S2). NOTCH1 (50%), FBXW7 (25%), IL7R (25%), NRAS (25%), DNMT3A (17%), PHF6 (17%), and 
GATA3 (17%) were the most common sequence variants in B-ALL (Supplement Fig. S5). Meanwhile, NRAS 
(17%), FLT3 (14%), KRAS (9%), SETD2 (7%), PAX5 (6%), and CREBBP (6%) were the most common sequence 
variants in B-ALL (Supplement Fig. S5).
Lollipop plots of the variants are shown in Supplemental Fig. S6. All NRAS variants were previously reported 
variants (COSMIC database, Supplement Table S2) or the same codon variant (p.Gly12Asp/Ser, p.Gly13Asp/
Val, p.Gln61Arg/Lys). All KRAS variants were also previously reported variants or the same codon variant 
(p.Gly12Asp/Ser, p.Gly13Asp, p.Leu23Arg, p.Ala146Val/Thr). Most of the FLT3 variants were known variants 
(previously found in hematologic malignancies, p.Asp835Asn/Tyr, p.Leu576Gln, p.Asn676Lys, et al.). About 50% 
of the PAX5 variants were also recurrent variants (p.Val26Gly, p.Ala322ArgfsTer19, p.Val26Gly).
Five of the nine NOTCH1 variants were known variants that had been found in hematologic malignancies 
(p.Arg1598Pro, p.Gln2503Ter, p.Glu2460Ter, p.Leu1585Gln, p.Phe1592Ser). Three of the four FBXW7 variants 
were known variants that were found in hematologic malignancies (p.Arg465His, p.Arg479Gln, p.Arg465His). 
Most of SETD2 were novel variants with no obvious hot spot mutations (seven of the eleven variants were 
frameshift or non-sense), as in the previous  study14. The CREBBP variants were commonly found (4/8) in the 
histone acetyltransferase (HAT) domain with missense mutations, consistent with the results of a previous 
 study15. Most of the PTPN11variants (4/5) were found in the Src homology 2 domain (SH2 domain, N-SH2 and 
C-SH), which are predominant region of mutation in hematologic  diseases16.
Somatic copy number variants. We found a total of 223 somatic CNV. CDKN2A/B (50%), CRLF2 (17%), 
GATA3 (8%), CSF2RA (8%), and BCOR (8%) were the most common CNV in T-ALL (Supplement Fig. S7). 
CDKN2A/B (31%), IKZF1 (16%), ETV6 (12%), ERG (12%), and RB1 (11%) were the most common CNV in 
B-ALL (Supplement Fig. S8).
Fifteen B-ALL patients had an IKZF1 alteration (Table 3). Seven patients had B-ALL with t(9;22)(q34;q11.2); 
BCR-ABL1. Six B-ALL, NOS patients had an IKZF1 gene deletion. Seven of thirteen B-ALL with t(9;22)
(q34;q11.2); BCR-ABL1 patients had an IKZF1 deletion (54%). Three of thirteen B-ALL with t(9;22)(q34;q11.2); 
BCR-ABL1 patients had a PAX5 deletion (23%).
CDKN2A/B by NGS and FISH. FISH for CDKN2A/B was performed upon the initial diagnosis of ALL. 
We compared the CDKN2A/B results between the FISH and NGS CNVs analyses. The overall agreement rate 
for CDKN2A/B was 83.7% (Table 4). Nine cases were positive for CDKN2A/B deletion according to NGS, but 
negative by FISH. Meanwhile, six cases were normal by NGS analysis, but deletion/duplication was confirmed 
by FISH.
Clinical effects of genetic alteration. Overall survival and relapse-free survival. Overall survival (OS) 
and relapse-free survival (RFS) are shown by cytogenetic groups in Fig. 3. There were statistically significant dif-
ferences in OS and RFS in childhood ALL, but not in adult ALL.
Clinical impact of IKZF1. IKZF1 alteration had adverse effects on OS and RFS only in childhood ALL 
(Fig. 4). No other genes had a consistent clinical effect in childhood or adult ALL (data not shown).
Table 2.  Germline pathogenic/likely pathogenic variants identified in Korean ALL patients. *Exonic deletion, 
exon 6-exon 9.
Patients Sex/age Diagnosis Gene Accession Nucleotide Amino acid %Variant dbSNP Syndrome Inheritance
ALL0009 Female/51 B-ALL, NOS TP53 NM_000546.5 c.733G > A p.Gly245Ser 40.3 rs28934575 Li-Fraumeni syndrome Autosomal dominant
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Discussion
NGS technology has been applied to a number of hematologic diseases. Many gene panels and several methods 
have been used to detect not only sequence variants, but also large gene deletions and duplications or gene 
 fusions15–19. In this study, we found a significant agreement rate between NGS and FISH for CDKN2A/B CNV 
detection. We also found significant IKZF1 deletions using an NGS CNV analysis. A presumed diagnosis of BCR-
ABL1-like ALL can be enabled using an NGS CNV analysis to test for genetic alterations in IKZF1 and JAK1/
JAK2 because the former (68%) and latter (55% among patients with CRFL2 rearrangement) are more prevalent 
in BCR-ABL1-like ALL than in other B-ALL sub-types2. Although we did not perform gene expression profiling 
and FISH, or RT-PCR for alterations commonly found in BCR-ABL1-like ALL, we found seven cases with IKZF1 
alterations in non-ALL with BCR-ABL, and these showed adverse clinical effects. We assume that the seven non-
ALL patients with BCR-ABL1 and an IKZF1 alteration are likely BCR-ABL1-like ALL.
In B-ALL, the most common pathogenic pathways are RAS signaling (~ 48%, NRAS, KRAS, PTPN11, FLT3, 
NF1, etc.) and Lymphoid development/differentiation (18–80%, PAX5, IKZF1, EBF1, etc.)2, 20, 21, and we found 
a similar distribution of genetic changes in this study (42% RAS signaling and 49% Lymphoid development/
differentiation variants were identified). The deletion of IKZF1 (~ 41.4%), CDKN2A/B (~ 36.9%), and PAX5 
(~ 25.5%) are most common in overall B-ALL21, 22. IKZF1 deletion has a poor prognostic effect and is more fre-
quent (60–90%) in B-ALL with BCR-ABL1 or high risk non-BCR-ABL1 ALL (~ 30%) than other B-ALL subtype, 
Figure 1.  Most common genetic alterations in T-cell lymphoblastic leukemia/lymphoma (T-ALL) and ETP 
(Early T-cell Precursor Acute Leukemia). Only ≥ two patients with gene-alterations are shown in the figure. Data 
were analyzed by OncoPrinter (cBioPortal Version 1.14.0, Gao et al., Sci. Signal. 2013 and Cerami et al., Cancer 
Discov. 2012). Truncating mutations (nonsense, frameshift deletion, frameshift insertion, splice site); inframe 
(inframe deletion, inframe insertion).
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as shown in our  results2, 11, 22, 23. Consistent with previous studies, our study showed that IKZF1 deletion was more 
frequent in the adult high-risk cytogenetic group (6/12, 50%) than in the overall B-ALL group (13/81, 16%). This 
high prevalence of IKZF1 deletion in the adult high-risk cytogenetic group might have occurred because most 
cases (11/12) were ALL with BCR-ABL1.
In T-ALL, we found recurrent somatic sequence variants and CNVs similar to those reported in previous 
 studies4, 5. The sequence variants of NOTCH1 (~ 50%), PHF6 (~ 20%), JAK3-IL7R (~ 30%), and FBXW7 (~ 18%) 
are common mutations in T-ALL4, 5, 22–24. CDKN2A/B deletion (50%, 6/12) is most common, as shown in previous 
studies (50–70%)22, 23. Although only two cases of ETP were enrolled in this study, the identified variants were 
among the recurrent genes in T-ALL or ETP (FLT3, WT1, NOTCH1, and IL7R)4, 5. There is a need for more ETP 
cases to reveal the genetic alterations in T-ALL among Koreans.
Skin fibroblasts are the only recommended control sample for germline mutations, because peripheral blood 
(PB) and bone marrow can be contaminated with leukemic cells, while other samples, such as saliva or buccal 
swab, can be also contaminated with PB. Further, clonal hematopoiesis can be observed in ~ 10% of the healthy 
population, and this rate increases with  age25. However, a skin biopsy is an invasive procedure, and as a result, 
such samples are not readily available. We therefore used CR-state bone marrow slides (acquired to test for 
residual leukemic cells) as the control for germline mutations. No apparent leukemic samples were obtained in 
our review of bone marrow morphology, or in the FISH, chromosome, flow-cytometry, and RT-PCR results. The 
variant allele fraction (VAF) and public population databases were used as filtering  tools26. Germline variants 
can have a VAF of > 33%, even in tumor  samples26; variants within that range have a high possibility of germline 
origin. Some presumably somatic variants registered in public databases, such as the Single Nucleotide Poly-
morphism database (dbSNP), the 1000 Genomes Project, the Exome Aggregation Consortium (ExAC) database, 
and the Human Gene Mutation Database (HGMD), may be of germline origin. We double checked the germline 
variants in both CR and leukemic samples. True germline variants (identified in CR samples) were also identified 
in paired leukemic samples with similar VAF. By contrast, true somatic variants (identified in leukemic samples) 
were either not found, or were found with very low VAF (< 1%) in paired CR.
Various syndromes increase the risk of ALL, with variable penetrance and preference. DS is the most com-
mon genetic cause of childhood leukemia. In an analysis of the National Registry of childhood tumors in the 
Figure 2.  Most common genetic alterations in B-cell lymphoblastic leukemia/lymphoma (B-ALL). Only ≥ seven 
patients with gene-alterations are shown in the figure. Data were analyzed by OncoPrinter (cBioPortal Version 
1.14.0, Gao et al., Sci. Signal. 2013 and Cerami et al., Cancer Discov. 2012). Truncating mutations (nonsense, 
frameshift deletion, frameshift insertion, splice site); inframe (inframe deletion, inframe insertion).
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United Kingdom, 131 of 142 leukemia patients with underlying genetic causes were DS  patients6, and an analy-
sis of approximately 18,000 European childhood ALL cases found that 2.4% of ALL patients also had  DS7. 
Other genetic diseases with connections to ALL include ataxia telangiectasia, Nijmegen breakage syndrome, 
neurofibromatosis type 1, familial ALL, and Noonan  syndrome7. Germline PAX5 and ETV6 mutations carry a 
high risk (high penetrance) of cancer, mainly  ALL7, 9, 27; bloom syndrome and constitutional mismatch repair 
deficiency syndrome also carry a moderate risk of ALL. Constitutional mismatch repair deficiency syndrome 
is more associated with T-cell lineage leukemia and lymphoma than B-cell  lineage28. However, this study found 
no pathogenic or likely pathogenic variants among the gene mutations (PAX5, ETV6, NF1, BLM, ATM, etc.) 
that have high penetrance for  ALL7. This may be because we enrolled a relatively small number of unselected 
sporadic cases. Moriyama et al. reported that only 0.79% (35/4,405) of sporadic childhood ALL cases have a 
potentially pathogenic ETV6  variant26.
In this study, we did identify only one pathogenic variant (TP53) among 81 genes associated with 23 syn-
dromes that are well known for their connection to hematologic malignancy. For example, Li-Fraumeni syndrome 
(TP53) is a well-known rare cancer syndrome. The most common cancers in patients with Li-Fraumeni syndrome 
are solid cancers (such as breast cancer, lung cancer, and bladder cancer)12. However, a somatic TP53 altera-
tion is strongly associated with low hypodiploidy ALL (~ 90%), disease relapse, and germline origin (~ 40%)29. 
Although hypodiploid ALL accounts for only 5% of childhood ALL cases, hypodiploid ALL patients should be 
tested for Li-Fraumeni syndrome because of its poor prognosis and the possibility of a germline TP53  mutation30.
We found germline copy number variation in CASP10. CASP10 is a causative gene for autoimmune lym-
phoproliferative syndrome (ALPS) type IIa, which is a very rare PID (primary immunodeficiency disorder). 
However, the association between exonic deletion of CASP10 and leukemia in our patient is unclear in this study. 
Table 3.  IKZF1 alteration cases.
Patients Sex Age group Diagnosis
Bone marrow 
transplant IKZF1 PAX5 Relapse
Clinical 
outcome
ALL0003 Female Adult B-ALL with BCR-ABL1 – Deletion Deletion – –
ALL0004 Female Adult B-ALL with BCR-ABL1 – Deletion Deletion – Expired
ALL0010 Female Adult B-ALL with BCR-ABL1 Allogenic Deletion – – –
ALL0011 Male Adult B-ALL, NOS – Deletion – Yes Expired
ALL0024 Female Child B-ALL, NOS – Deletion – Yes –
ALL0026 Male Child B-ALL, NOS Allogenic Deletion – Yes Expired





Allogenic Missense muta-tion – Yes Expired
ALL0049 Female Adult B-ALL, NOS Allogenic Deletion Deletion – –
ALL0051 Male Child B-ALL, NOS – Deletion Deletion – –
ALL0062 Male Adult B-ALL with BCR-ABL1 – Deletion – – –
ALL0064 Female Adult B-ALL with BCR-ABL1 Allogenic Deletion – – –
ALL0065 Female Adult B-ALL, NOS Allogenic Frameshift muta-tion – – –
ALL0069 Male Child B-ALL with BCR-ABL1 Allogenic Deletion – – –
ALL0083 Female Adult B-ALL with BCR-ABL1 – Deletion Deletion – –
Table 4.  Comparison of FISH and NGS results for CDKN2A/B deletion/duplication. Agreement rate: 83.7%.
NGS (next generation sequencing) results
Deletion Duplication Normal Total
FISH (fluorescent in situ hybridization) results
Deletion 20 1 21
Duplication 1 5 6
Normal 9 56 65
Not tested 1 1
Total 30 1 62 93
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In a previous study, similar exonic deletion of CASP10 had only been found in a patient with systemic juvenile 
idiopathic arthritis with incomplete penetrance (healthy relative with the same CNV)13. In this case, we could 
not find any medical history associated with ALPS in our patient.
More than 300 distinct disorders and genes of PID have been classified by the International Union of Immu-
nological Societies PID expert  committee31. An increase in leukemia/lymphoma with PID (including ALPS) 
is well known and  expected32. Although the mechanism of leukemogenesis in PID remains unclear, intrinsic 
(cancer predisposition parallel to the immunological defect) and extrinsic (chronic infections, inflammation, 
or loss of immunosurveillance) mechanisms have been proposed by Hauck et al.33. Notably, in this study, we 
identified five PID-associated sequence variants and one CNV. All these sequence variants were heterozygous 
autosomal recessive PID associated variants. Therefore, the association between these variants and leukemia in 
our patients is unclear. However, some studies have reported an increased risk of cancer in heterozygous carri-
ers of autosomal recessive PID associated variants, heterozygous BLM (Bloom syndrome, AR) mutations, and 
Figure 3.  Clinical outcomes by cytogenetic group. Overall survival (OS) and relapse-free survival (RFS) were 
both found to be statistically significant (P < 0.5) in child B-cell lymphoblastic leukemia/lymphoma (B-ALL). 
RFS was statistically significant in adult B-ALL. Child B-ALL were classified into good cytogenetic (Gcyto, 
n = 26), intermediate cytogenetic (Icyto, n = 26), and high cytogenetic risk (Hcyto, n = 6) groups. Adult B-ALL 
were classified into Gcyto (n = 2), Icyto (n = 9), and Hcyto (n = 12) groups.
Figure 4.  Clinical outcomes by IKZF1 alteration. IKZF1 alteration had a prognostic impact on overall survival 
(OS) and relapse-free survival (RFS) in child B-cell lymphoblastic leukemia/lymphoma (B-ALL), particularly in 
the good cytogenetic (Gcyto) and intermediate cytogenetic risk (Icyto) groups. Child B-ALL were classified into 
Gcyto (n = 26) and Icyto (n = 26) groups.
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heterozygous ATM (Ataxia-telangiectasia, AR)  mutations34, 35. Moreover, Qin, N. et al. have reported a risk of 
subsequent cancer among long-term survivors of childhood cancer with germline pathogenic/likely pathogenic 
mutations (DNA repairs genes which are mostly included in PID-associated genes, such as BLM, FANCA, BRCA2 
LIG4, NBN, etc.)36. Therefore, further studies should continue elucidating these uncertain significant variants 
of PID-associated variants.
Our study had several limitations. First, we enrolled a relatively small number of cases. Second, we did not use 
skin fibroblasts in our search for germline mutations. Third, we did not perform a familial study or any clinical 
or physical investigations of the identified germline variants.
Conclusion
We found recurrent somatic alterations in Korean ALL patients. Further, we identified the low probability of 
germline mutation predisposition in unselected sporadic Korean ALL patients. We also demonstrated the useful-
ness of NGS technology, which provides comprehensive genetic information.
Methods
Study population and samples. We selected paired initial-diagnosis and complete remission (CR) bone 
marrow samples from patients diagnosed with ALL at Samsung Medical Center from 2008 to 2012.
The Institutional Review Board at Samsung Medical Center approved this study (IRB No. 2015-11-053), and 
informed consent was obtained from all participants. All experiments were performed in accordance with the 
relevant guidelines and regulations.
To detect germline mutations, we used bone marrow slides that were obtained when the patients were in CR. 
In total, 31 (33.3%) patients received allogenic stem cell transplantation. CR status bone marrow slides before 
allogenic stem cell transplantation were used to accurately detect patient germline mutations. The morphology, 
chromosome, FISH, and immunophenotyping results were reviewed, and bone marrow slides with no apparent 
residual leukemic cells were selected as control samples.
Conventional study. A chromosome study was conducted using a standard method, and the karyotypes 
are described according to the International System for Human Cytogenetic Nomenclature. Multiplex reverse 
transcription polymerase chain reaction (RT-PCR) was performed to detect recurrent translocation (HemaVi-
sion kit, DNA Technology, Aarhus, Denmark). FLT-ITD mutation analyses (by fragment length polymorphism) 
and FISH for CDKN2A/B were performed as well.
Targeted gene sequencing. Gene panel. From a literature review, we selected 500 genes found to be 
significantly mutated in ALL (Supplement Table S5). Our gene  panel17 included the following: cell cycle and p53 
signaling pathway (ATM, CDKN1B, CDKN2A, CDKN2B, RB, TP53, etc.), chromatin structure modifiers and 
epigenetic regulators (ARID1A, BMI1, CHD1, CHD4, CHD9, CREBBP, CTCF, DNMT3A, EED, EP300, EZH2, 
KDM5C, KDM6A, KMT2A, KMT2C, KMT2D, NR3C1, PHF6, SETD2, SUZ12, WHSC1, etc.), JAK-STAT signal-
ing pathway (CRLF2, IL2RB, IL7R, JAK1, JAK2, JAK3, PTPN2, SH2B3, STAT3, TYK2, etc.), DNA repair (MSH2, 
MSH6, ZFHX4, etc.), NOTCH pathway (FBXW7, NOTCH1, etc.), PI3K-AKT-mTOR signaling pathway (AKT2, 
PIK3CD, PIK3R1, PTEN, etc.), RAS pathway (BRAF, CBL, FLT3, KRAS, NF1, NRAS, PTPN11, etc.), and tran-
scriptional processes (BCL11B, DNM2, ERG, GATA3, LMO2, MYB, RELN, TAL1, TBL1XR1, TLX1, TLX3, WT1, 
etc.).
Predisposition syndrome to hematologic malignancies. We included 23 well known predisposi-
tion syndromes (81 genes) in our next generation sequencing (NGS) panel: ataxia pancytopenia syndrome 
(SAMD9L), ataxia telangiectasia (ATM), Bloom syndrome (BLM), constitutional mismatch repair deficiency 
syndrome (MLH1, MSH2, MSH6, PMS2, and EPCAM), Diamond-Blackfan anemia (GATA1, RPL5, RPL11, 
RPL15, RPL23, RPL26, RPL27, RPL31, RPL35a, RPL36, RPS7, RPS10, RPS15, RPS17, RPS19,RPS24, RPS26, 
RPS27, RPS27A, RPS28, RPS29, and TSR2), dyskeratosis congenita (DKC1, TERC, TERT, NOP10, NHP2, TINF2, 
WRAP53, CTC1, RTEL1, ACD, PARN, and NAF1), familial acute myeloid leukemia (CEBPa), familial platelet 
disorder with propensity to myeloid malignancy (RUNX1), Fanconi anemia (FANCA, FANCB, FANCC, BRCA2, 
FANCD2, FANCE, FANCF, FANCG, FANCI, BRIP1, FANCL, FANCM, PALB2, RAD51C, SLX4, ERCC4, RAD51, 
BRCA1,UBE2T, XRCC2, and MAD2L2), GATA2-spectrum disorders (GATA2), Li Fraumeni (TP53), Ligase IV 
syndrome (LIG4), neurofibromatosis (NF1and SRP72), Nijmegen breakage syndrome (NBN), Noonan syn-
drome (PTPN11), Noonan-like syndrome (CBL), severe congenital neutropenia 3 (DDX41 and HAX1), severe 
congenital neutropenia (ELANE), Shwachman-Diamond syndrome (SBDS), susceptibility to ALL 3 (PAX5), 
thrombocytopenia 2 (ANKRD26), thrombocytopenia 5 (ETV6), and Wiskott Aldrich Syndrome (WAS).
Data analysis. The data analysis was conducted using previously described methods (Supplement Fig. S9)17. 
After sequencing, we aligned the reads to human genomic reference sequences (GRCh37) using the Burrows–
Wheeler alignment tool. The Genome Analysis Tool Kit (Broad Institute) was used for variant calling. Pindel was 
used for crosscheck insertion and mutation deletion. All mutations were annotated using ANNOVAR and VEP 
software. Variants were further examined by visual inspection using the Integrative Genomic Viewer. Anno-
tated variants were classified using automated algorithm software, DxSeq Analyzer (Dxome, Seoul, Korea), by 
applying the standards and guidelines of the American College of Medical Genetics and Genomics and the 
Association for Molecular  Pathology37. ExomeDepth (1.1.10), an R package, was used to detect exon- and gene-
level CNVs in target regions, followed by visualization using a base-level read depth normalization algorithm 
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implemented in a DxSeq Analyzer (Dxome, Seoul, Korea)17. To obtain reliable results, we used cutoff values for 
the average depth and % covered (30×) of 700× and 99%, respectively. The minimal reportable VAF was ≥ 1%.
Statistical analysis. Differences in survival according to mutation group were analyzed using Kaplan–
Meier estimates. A P-value of < 0.05 was considered to be statistically significant. All statistical analyses were 
performed in PASW Statistics 20.0.
Ethics declarations. The Institutional Review Board at Samsung Medical Center approved this study (IRB 
No. 2015-11-053), and informed consent was obtained from all participants.
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